These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25311381)

  • 41. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis.
    Fujii Y; Nouso K; Matsushita H; Kariyama K; Sakurai T; Takahashi Y; Chiba H; Hui SP; Ito Y; Ohta M; Okada H
    J Appl Lab Med; 2020 Nov; 5(6):1206-1215. PubMed ID: 32674154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males.
    Peng K; Mo Z; Tian G
    Am J Med Sci; 2017 Mar; 353(3):236-241. PubMed ID: 28262209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
    Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH.
    Gottlieb A; Leven AS; Sowa JP; Borucki K; Link A; Yilmaz E; Aygen S; Canbay A; Porsch-Özcürümez M
    Digestion; 2021; 102(5):671-681. PubMed ID: 33080603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease.
    Mager DR; Mazurak V; Rodriguez-Dimitrescu C; Vine D; Jetha M; Ball G; Yap J
    JPEN J Parenter Enteral Nutr; 2013 Jul; 37(4):517-28. PubMed ID: 23223552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
    J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins.
    Lucero D; Miksztowicz V; Gualano G; Longo C; Landeira G; Álvarez E; Zago V; Brites F; Berg G; Fassio E; Schreier L
    Clin Chim Acta; 2017 Oct; 473():1-8. PubMed ID: 28802640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipoprotein profile in patients who survive a stroke.
    Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P
    Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.